Organigram Global Inc.

NASDAQ: OGI · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Moncton, NBCIK 0001620737Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 62

v0.1 · 5/100 weight · pillars only

↑ workforce scale, balance-sheet leverage · ↓ filing timeliness, Piotroski F

Methodology →

Revenue TTM

$198.4M

Rev growth YoY (TTM)

+42.7%

Net income (FY)

-$33.4M

Employees

1,093

Market cap

$145.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$33.4M-45.4M CAD2024

Total assets$302.1M407.9M CAD2024

Liabilities$75.5M101.9M CAD2024

Revenue by segment

Filed disclosures · FY2025

By product

International Business To Business69%

Wholesale To Licensed Producers Revenue24%

Direct To Patient Medical Revenue6%

Other Revenue0%

By geography

Not disclosed.

The read

Organigram Global Inc. earned -$33.4M in FY2024 net income.

Peers · Healthcare

Agenus Inc.68B Immunic, Inc.——CVRx, Inc.50D Vor Biopharma Inc.——

Key facts

CEOJames H. Yamanaka

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersMoncton, NB

ExchangeNASDAQ: OGI

Employees1,093

IPO date2019-05-21

Latest filings

6-K2026-05-12 6-K2026-05-06 6-K2026-04-16 6-K2026-03-31 6-K2026-03-23 6-K2026-03-11 6-K2026-03-09 6-K2026-03-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.